BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that Swissmedic, the regulatory authority for Switzerland, has granted approval for ABRAXANE® (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) as a treatment for metastatic pancreatic cancer (in combination with gemcitabine), and as a treatment for metastatic breast cancer.1 ABRAXANE has been approved in more than 30 countries for metastatic pancreatic cancer and over 40 countries for metastatic breast cancer.
Help employers find you! Check out all the jobs and post your resume.
